These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 31818849)

  • 1. A Tumor-in-Host DEB-Based Approach for Modeling Cachexia and Bevacizumab Resistance.
    Tosca EM; Rocchetti M; Pesenti E; Magni P
    Cancer Res; 2020 Feb; 80(4):820-831. PubMed ID: 31818849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling tumor growth inhibition and toxicity outcome after administration of anticancer agents in xenograft mice: A Dynamic Energy Budget (DEB) approach.
    Terranova N; Tosca EM; Borella E; Pesenti E; Rocchetti M; Magni P
    J Theor Biol; 2018 Aug; 450():1-14. PubMed ID: 29680449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth after administration of an anti-angiogenic agent, bevacizumab, as single-agent and combination therapy in tumor xenografts.
    Rocchetti M; Germani M; Del Bene F; Poggesi I; Magni P; Pesenti E; De Nicolao G
    Cancer Chemother Pharmacol; 2013 May; 71(5):1147-57. PubMed ID: 23430120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Dynamic Energy Budget (DEB) based modeling framework to describe tumor-in-host growth inhibition and cachexia onset during anticancer treatment in
    Tosca EM; Rocchetti M; Magni P
    Oncotarget; 2021 Jul; 12(14):1434-1441. PubMed ID: 34262653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways.
    Greening DW; Lee ST; Ji H; Simpson RJ; Rigopoulos A; Murone C; Fang C; Gong S; O'Keefe G; Scott AM
    Oncotarget; 2015 Nov; 6(35):38166-80. PubMed ID: 26517691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
    Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
    Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.
    Conley SJ; Baker TL; Burnett JP; Theisen RL; Lazarus D; Peters CG; Clouthier SG; Eliasof S; Wicha MS
    Breast Cancer Res Treat; 2015 Apr; 150(3):559-67. PubMed ID: 25833208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXF1 promotes angiogenesis and accelerates bevacizumab resistance in colorectal cancer by transcriptionally activating VEGFA.
    Wang S; Xiao Z; Hong Z; Jiao H; Zhu S; Zhao Y; Bi J; Qiu J; Zhang D; Yan J; Zhang L; Huang C; Li T; Liang L; Liao W; Ye Y; Ding Y
    Cancer Lett; 2018 Dec; 439():78-90. PubMed ID: 30253191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs.
    Hutchinson LG; Mueller HJ; Gaffney EA; Maini PK; Wagg J; Phipps A; Boetsch C; Byrne HM; Ribba B
    CPT Pharmacometrics Syst Pharmacol; 2016 Nov; 5(11):636-645. PubMed ID: 27863175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer.
    Pham E; Yin M; Peters CG; Lee CR; Brown D; Xu P; Man S; Jayaraman L; Rohde E; Chow A; Lazarus D; Eliasof S; Foster FS; Kerbel RS
    Cancer Res; 2016 Aug; 76(15):4493-503. PubMed ID: 27325647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis.
    Mollard S; Ciccolini J; Imbs DC; El Cheikh R; Barbolosi D; Benzekry S
    Oncotarget; 2017 Apr; 8(14):23087-23098. PubMed ID: 28416742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response.
    Cesca M; Morosi L; Berndt A; Fuso Nerini I; Frapolli R; Richter P; Decio A; Dirsch O; Micotti E; Giordano S; D'Incalci M; Davoli E; Zucchetti M; Giavazzi R
    Mol Cancer Ther; 2016 Jan; 15(1):125-35. PubMed ID: 26494857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy inhibition sensitizes colon cancer cells to antiangiogenic and cytotoxic therapy.
    Selvakumaran M; Amaravadi RK; Vasilevskaya IA; O'Dwyer PJ
    Clin Cancer Res; 2013 Jun; 19(11):2995-3007. PubMed ID: 23461901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
    Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
    Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
    Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
    J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dichloroacetate reverses the hypoxic adaptation to bevacizumab and enhances its antitumor effects in mouse xenografts.
    Kumar K; Wigfield S; Gee HE; Devlin CM; Singleton D; Li JL; Buffa F; Huffman M; Sinn AL; Silver J; Turley H; Leek R; Harris AL; Ivan M
    J Mol Med (Berl); 2013 Jun; 91(6):749-58. PubMed ID: 23361368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma.
    Mao XG; Wang C; Liu DY; Zhang X; Wang L; Yan M; Zhang W; Zhu J; Li ZC; Mi C; Tian JY; Hou GD; Miao SY; Song ZX; Li JC; Xue XY
    Oncotarget; 2016 Jul; 7(30):47808-47820. PubMed ID: 27329597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI.
    Chen YF; Yuan A; Cho KH; Lu YC; Kuo MY; Chen JH; Chang YC
    PLoS One; 2017; 12(11):e0187824. PubMed ID: 29121075
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Population Dynamic Energy Budget-Based Tumor Growth Inhibition Model for Etoposide Effects on Wistar Rats.
    Tosca EM; Pigatto MC; Dalla Costa T; Magni P
    Pharm Res; 2019 Jan; 36(3):38. PubMed ID: 30635794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab followed by chemotherapy is potential therapy for gastric cancer.
    Lv Y; Song L; Chang L; Liu Y; Zhang X; Wang Y; Wang L; Liu W
    J BUON; 2016; 21(6):1466-1470. PubMed ID: 28039709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.